A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin\'s lymphoma (NHL).
Epistemonikos ID: 68ee09116d0bf5cd7074e589f0e64aee5a673297
First added on: May 20, 2024